Mira Pharmaceuticals in discussion with MSK Cancer Center for oral ketamine use

Mira Pharmaceuticals is in advanced discussions with Memorial Sloan Kettering Cancer Center – MSK – to initiate a preclinical study evaluating Mira‘s novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression. Mira’s novel oral ketamine analog presents an alternative due to its potential for high oral bioavailability and lack of interaction with mu opioid receptors, which potentially enhances its safety profile. The aim of this collaboration would be to assess the potential of oral Ketamir-2, in comparison with non-oral administration of ketamine, to alleviate symptoms of cancer pain in a rodent animal model. In parallel, Mira is exploring the effects of Ketamire-2 on neuropathic pain within the framework of its collaboration with Pharmaseed. This therapeutic could potentially streamline the regulatory approval process by leveraging its novel properties, allowing for an accelerated clinical studies as combined Phase 1/2 clinical trial. Successful outcomes from the preclinical study could potentially accelerate the pathway for FDA approval of an Investigational New Drug Application for Ketamir-2 over the next year and open opportunities for non-dilutive funding.